NeuroPace (NPCE) says it remains on track to submit NAUTILUS data to the FDA for potential IGE indication expansion in the second half of 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- NPCE Upcoming Earnings Report: What to Expect?
- NeuroPace ‘commends’ CMS for maintaining FY25 epilepsy reimbursement structure
- Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
- NeuroPace Appoints New CFO Amid Strategic Shift
- NeuroPace CFO Rebecca Kuhn to depart, Patrick Williams to succeed